Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia
Optimi Health completed its latest GMP production batch of MDMA finished drug product at its Princeton, British Columbia facility, sized to supply three programs: the proposed Canadian Phase 3 PTSD trial, a MAPS-partnered trial in Israel, and commercial export to Australia. The proposed Canadian Phase 3 trial would enroll up to 100 veterans and frontline workers receiving two MDMA-assisted therapy sessions, with the CAPS-5 scale as the primary endpoint; it is expected to begin in 2027.
Key figures
- Drug Name
- MDMA (3,4-methylenedioxymethamphetamine) capsules
- Phase Of Trial
- Phase 3 (proposed, expected to begin 2027)
- Trial participants
- up to 100 veterans and frontline workers
- Commercial supply since
- 2024
- Australian clinicians trained
- more than 750
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.